Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02369653 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 512
- Enrollment target
NCT02369653 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 512 participants.
The verdict
NCT02369653, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 512 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)
Interventions
- DRUG Apixaban
- OTHER No systemic anticoagulant prophylaxis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2015-10-22 |
| Est. Completion | 2021-07-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02369653
The ClinicalTrials.gov registry entry for NCT02369653 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 512 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT02369653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02369653 about?
NCT02369653 is a clinical study titled "A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase". The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a ...
What is the current status of trial NCT02369653?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 512 participants. The study started on 2015-10-22. Estimated completion is 2021-07-07.
What interventions are being tested in trial NCT02369653?
The interventions under investigation include: Apixaban (DRUG), No systemic anticoagulant prophylaxis (OTHER).
Who is sponsoring clinical trial NCT02369653?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.